查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1863154

全球神經調控設備市場：洞察、競爭格局及市場預測（至2032年）

Neuromodulation Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

神經調控設備市場摘要

  • 全球神經調控設備市場預計將從 2024 年的 78.6204 億美元成長到 2032 年的 161.111 億美元，反映出強勁且持續的成長。
  • 全球神經調控設備市場在 2025 年至 2032 年的預測期內將以 9.44% 的複合年成長率成長。
  • 神經調控設備市場正經歷快速成長，這主要得益於全球慢性疾病（如疼痛、癲癇和憂鬱症）盛行率的上升。此外，技術的顯著進步也推動了這一成長，使得設備體積更小、更強大、更智慧。有利的監管政策和完善的報銷體係也提高了這些療法的可及性。總而言之，對有效、長期治療神經系統疾病和慢性疾病的方案日益成長的需求，正在催生一個強勁且永續發展的市場。
  • 神經調節設備市場的主要企業包括：雅培實驗室、史密斯醫療、貝朗醫療、百特國際、波士頓科學公司、LivaNova PLC、美敦力、Nevro公司、雅培、史賽克、歐姆龍公司、Stimwave LLC、皇家飛利浦公司、金佰利公司、EndoStimi. SA、Cyber​​onics、DyAnsys公司、NanoVibronix公司和ElectroCore公司。
  • 由於慢性疼痛和神經病變負擔沉重、人們意識的提高、政府的支持計劃、FDA 的頻繁核准以及持續的產品創新，預計北美將繼續保持其在神經調節設備市場的主導地位。
  • 在神經調節設備市場按設備類型分類的區隔市場中，預計到 2024 年，脊髓刺激設備類別將佔最大的市場佔有率。

神經調控設備市場成長要素

  • 慢性病和神經系統疾病盛行率上升推動神經調控設備市場蓬勃發展：全球範圍內，越來越多的疾病需要透過神經調控設備進行治療，其中包括慢性疼痛、癲癇、帕金森氏症以及難治性憂鬱症。隨著這些疾病的日益普遍，對有效、長期治療方案的需求也隨之激增。
  • 技術進步：持續的技術創新正成為市場擴張的強大催化劑。近期趨勢包括開發更小巧、更強大、可充電的設備，這些設備能夠減輕手術負擔、延長設備使用壽命並提高患者的便利性。諸如自適應深部腦部刺激等「閉合迴路」神經調控系統的出現，代表著模式轉移，該系統能夠即時監測神經活動，並僅在需要時進行刺激。這不僅提高了治療效果，還最大限度地減少了副作用並最佳化了能量利用。此外，神經調控技術的應用範圍不斷擴大，涵蓋了運動障礙以外的疾病，例如憂鬱症、慢性疼痛、癲癇甚至睡眠障礙，這顯著擴大了潛在市場。因此，疾病盛行率的不斷上升，加上技術的快速發展，正在強化神經調控技術作為治療複雜、長期神經系統疾病和慢性疾病的創新解決方案的作用。

患者和醫療專業人員都越來越傾向於選擇微創治療方法，這一趨勢極大地推動了神經調控設備的應用。植入式神經調控手術通常被認為是治療慢性疼痛、運動障礙和泌尿系統疾病的微創替代方案，優於傳統手術。與開放性手術相比，植入式神經調控手術通常切口較小、住院時間更短、恢復更快、術後併發症更少，從而提高患者滿意度並降低醫療成本。

除了這些手術操作的優勢外，經皮植入技術、微型化導線和磁振造影相容設備等技術創新進一步降低了手術風險，並使更多患者能夠接受這些手術。重要的是，微創神經調控在門診和日間手術中也越來越受歡迎，這與醫療產業向以價值為導向的醫療和成本效益的轉變相一致。隨著許多市場的健保政策擴大到涵蓋神經調控療法，以及設備製造商不斷改進治療方式，預計這些干預措施的微創特性仍將是已開發國家和新興醫療保健系統推廣應用的關鍵促進因素。

神經調控設備市場報告區隔

本神經調控設備市場報告全面概​​述了全球神經調控設備市場，重點分析了關鍵趨勢、成長促進因素、挑戰和機會。報告按設備類型、應用、最終用戶和地區對市場進行了詳細區隔，並深入剖析了北美、歐洲和亞太等主要市場的競爭格局、監管環境和市場動態。報告詳細介紹了行業領導者的概況和最新的產品創新，為企業提供了識別市場潛力、制定戰略規劃以及把握快速成長的神經調控設備市場新機會所需的重要數據。

神經調控設備是一種醫療技術，它透過刺激神經系統的特定區域來改變神經活動。這些刺激可以包括電訊號、磁場或化學物質。其目的是「調節」或使受疾病或損傷影響的神經組織功能恢復正常。

神經調控設備市場正經歷顯著成長，這主要得益於多種因素的共同作用。慢性疼痛、帕金森氏症、癲癇、自發性震顫等神經系統疾病以及難治性憂鬱症等精神疾病在全球的日益普遍，是推動市場成長的主要因素。日益加重的疾病負擔促使人們對有效且長期的治療方案的需求不斷成長。此外，技術的顯著進步也使這些設備更加有效且易於使用。小型可充電植入、能夠即時回應神經活動的「封閉回路型」系統以及經顱磁刺激 (TMS) 等非侵入性療法的開發，都在不斷擴大這些設備的應用範圍。此外，更有利的法規環境和更完善的報銷政策也使患者更容易獲得這些治療。這包括監管機構廣泛核准神經刺激設備的新用途，以及保險公司提供更全面的保險覆蓋。最後，全球人口老化以及與老齡化相關的神經系統疾病和慢性疼痛發病率的上升，進一步推動了市場的強勁成長。

根據發表在「柳葉刀神經病學」上的一項關於2021年全球疾病負擔（GBD）研究的重要分析，2021年全球將有34億人受到神經系統疾病的影響，佔全球人口的43%。這使得神經系統疾病成為全球疾病和殘疾的主要原因之一。其中最常見的疾病是緊張性頭痛（影響約20億人）和偏頭痛（影響約11億人）。神經調控設備，例如靶向枕神經的設備，透過阻斷疼痛訊號，可以有效控制慢性頭痛和偏頭痛。此外，自1990年以來，糖尿病神經病變患者人數增加了兩倍多，在2021年達到2.06億。神經調控設備正擴大用於治療神經損傷和相關疼痛。

根據世界衛生組織（世衛組織）的數據，全球約有5,000萬人患有癲癇。神經調控裝置，例如迷走神經刺激設備和反應性神經刺激設備，透過降低癲癇發作的頻率和嚴重程度，為治療提供了重要的選擇，特別適用於藥物難治性癲癇患者。

根據最新的GLOBOCAN 2022預測，全球將新增約2,000萬例癌症病例，並有970萬人死於癌症，五年患病人數將達5,350萬人。最常見的癌症是肺癌（248萬例）、乳癌（230萬例）、大腸癌（193萬例）、攝護腺癌（147萬例）和胃癌（9.7萬例）。整體而言，五分之一的人一生中會罹患癌症，九分之一的男性和十二分之一的女性會死於癌症。雖然高所得國家的癌症發生率較高，但由於早期檢測和治療機會有限，中低收入地區的癌症死亡率仍居高不下。展望未來，預計到2050年，全球癌症病例將增加至3,500萬例，比2022年增加77%。許多癌症患者會經歷神經病變疼痛，而這種疼痛通常難以透過常規治療方法來控制。先進的神經調控設備正被用於為這些患者提供顯著的疼痛緩解。

持續不斷的新產品上市和監管核准是神經調控設備市場的主要推動力。美敦力公司用於核准。與提供固定、連續刺激的傳統DBS系統不同，aDBS平台能夠即時監測患者的腦部活動，重點關注局部場電位（LFP）和BETA波振盪－帕金森氏症運動症狀的生物標記。然後，它會根據患者在各種情況下（包括藥物週期、休息和身體活動）的神經系統狀態動態調整刺激參數。這項特性不僅提高了治療的精準度，也減少了不必要的刺激，從而在最大限度減少運動障礙等副作用的同時，有望改善治療效果。此外，BrainSense電極識別器的加入簡化了編程，使臨床醫生能夠更有效率地進行個人化治療，為神經調控技術的發展樹立了新的標竿。

主要的障礙在於設備和植入手術的高昂費用，這限制了患者的可及性，尤其是在開發中國家。訓練有素的專業人員短缺加劇了這個問題，因為成功實施這種治療方法需要一個專業的、多學科的團隊，而缺乏此類專業知識可能導致患者療效不佳。此外，神經調控設備被歸類為高風險產品，導致核准流程漫長而複雜，可能會延緩創新產品的商業化進程。最後，患者和醫生的猶豫也是一大障礙：患者可能擔心接受侵入性手術，而一些醫生可能更傾向於使用更傳統、更熟悉的治療方法，而不是神經調控。

神經調控設備市場區隔分析 神經調控設備市場 - 依設備類型、應用、類型、最終用戶、地區分類

脊髓刺激設備療法主要受主流市場接受度的推動，預計2024年將佔全球神經調控設備市場佔有率的45%以上。世界衛生組織（WHO）（2023年）的數據顯示，約有6.19億人患有腰痛，預計到2050年這一數字將上升至8.43億。同時，歐洲疼痛聯盟（2023年）報告稱，全球約有7.4億人一生中至少會經歷一次劇烈疼痛，其中近20%的人患有持續超過三個月的慢性疼痛。

脊髓刺激設備（SCS）作為治療方法，正日益受到歡迎。 SCS透過向脊髓刺激設備輸送靶向電脈衝，阻斷疼痛訊號到達大腦，從而顯著改善患者的治療方法品質。

此外，美國國立衛生研究院 (NIH) 於 2023 年發表的一項研究表明，10% 至 40% 的患者在脊椎手術後會患上腰椎手術失敗症候群 (FBSS)。隨著椎間盤突出、脊椎狹窄和椎間盤退化性疾病等疾病的脊椎手術數量增加，FBSS 的盛行率也持續上升。由於重複手術風險高且往往無法提供持久的疼痛緩解，脊髓刺激設備正逐漸被認為是有效的替代方案。

2024 年 4 月，美敦力公司獲得 FDA核准推出 Inceptiv™，這是首個閉迴路 SCS 系統，它利用即時生物回饋（誘發複合動作電位，ECAP）自動調節閉合迴路，即使在日常活動中也能保持最佳治療效果。

2023年4月，百多力（Biotronik）的Prospera脊髓刺激系統獲得FDA核准。該系統採用RESONANCE技術，這是首個多相刺激模式；同時還配備了Embrace One系統，這是一種以患者為中心的護理模式，可提供自動化、客觀的日常遠端核准、持續管理和支援。該系統還包括HomeStream遠端系統管理、可充電植入，並相容於全身MRI成像。

這些進步都凸顯了 SCS 市場的發展軌跡，即從需要定期在診所進行調整的傳統固定輸出設備，轉向強調遠端照護、個人化和工作流程效率的智慧自適應系統。

疼痛管理領域將在神經調控設備市場佔主導地位，預計2024年將佔全球銷售額的58%左右。這一主導地位主要源自於慢性疼痛患者群體龐大且不斷成長，對全球健康和經濟帶來了沉重負擔。日益嚴重的鴉片類藥物危機促使醫療保健領域發生重大轉變，轉向非成癮性、無藥物的替代療法，例如神經調控。這些醫療設備正日益被視為安全有效的長期解決方案。包括脊髓刺激設備等更精密、更易於使用且更有效的設備在內的重大技術進步進一步強化了這一趨勢。這些技術創新，加上有利的報銷政策以及患者和醫療保健提供者日益增強的認知，正在鞏固神經調控設備在疼痛管理領域的市場主導地位。

預計到2024年，由於臨床療效顯著、應用廣泛以及監管核准和報銷機制的強力支持，侵入性神經調控設備將佔全球市場佔有率的85%以上。脊髓刺激設備、深層腦部刺激器、迷走神經刺激設備神經刺激器和薦骨神經刺激器等侵入性設備廣泛用於治療慢性疼痛、帕金森氏症、癲癇、憂鬱症、尿失禁等疾病，其療效已得到證實，贏得了醫生和患者的信賴。

近年來，封閉回路型刺激、多相波形、小型化和磁振造影相容植入以及遠端監測等技術的進步，進一步提升了安全性、有效性和易用性。慢性疼痛仍然是推動脊髓刺激器市場發展的主要因素，其中腰痛和腰椎手術失敗症候群的日益普遍，進一步鞏固了脊髓刺激設備的市場主導地位。此外，與因臨床檢驗和應用有限而促使分散的非侵入性治療領域不同，美敦力、雅培、波士頓科學、Nevro、百多力和Saluda等領先企業持續加強對侵入性治療方案的投資。這些因素共同作用，預計2024年，侵入性神經調控設備將在全球市場佔主導地位。

預計到2024年，醫院將繼續主導神經調控設備市場，佔超過85%的市場佔有率，並在預測期內維持收入成長率和複合年成長率的主導地位。這一主導地位主要歸功於醫院作為複雜外科植入手術（例如脊髓刺激設備、深層腦部刺激器和迷走神經刺激設備）的主要中心，需要先進的基礎設施、經驗豐富的神經外科醫生和多學科醫療團隊。此外，醫院還提供全面的術前評估、術中監測和術後康復，為患者和醫生創造了良好的治療環境。醫院也受惠於完善的保險報銷體系，使其能夠實施更多高成本的植入式神經調控設備。慢性疼痛、神經病變和腰椎手術失敗症候群日益嚴重的負擔正在推動住院和手術量的增加，進一步促進了設備的使用。此外，技術的不斷進步、與醫療技術公司的合作以及臨床試驗的參與，正在鞏固醫院作為神經調控治療卓越中心的地位。相較之下，門診中心和診所雖然也在發展，但主要局限於後續觀察治療和非侵入性神經調控療法，導致市佔率不斷萎縮。

根據美國疾病管制與預防中心（CDC，2023）的數據，2021年美國有20.9%的成年人（5,160萬人）報告患有慢性疼痛，其中6.9%（1,710萬人）患有嚴重慢性疼痛，影響日常生活。此外，約有290萬成年人患有活動性癲癇（CDC，2024），阿茲海默症協會（2024）報告稱，美國有690萬65歲及以上的老年人患有阿茲海默症。帕金森氏症的盛行率也在上升，每年新增病例近9萬例，現有病例超過100萬例，預計2030年將達到120萬例（帕金森基金會，2022）。

歐洲神經調控設備市場趨勢

歐洲神經調控設備市場正蓬勃發展，規模僅次於北美，預計2024年將佔全球市場佔有率的約21%。這一成長主要受以下幾個關鍵趨勢驅動：慢性病盛行率上升和人口老化。這些趨勢共同導致帕金森氏症、慢性疼痛和癲癇等疾病的患者群體不斷擴大。技術進步也是重要的推動因素，市場上湧現越來越多的「智慧」封閉回路型系統以及小型可充電、非侵入式設備，這些設備能夠改善患者的治療效果和舒適度。此外，儘管監管和報銷環境可能較為複雜，但許多歐洲主要國家已經建立了相應的框架來支援這些技術的應用。

亞太地區神經調控設備市場趨勢

亞太地區正成為全球神經調控設備成長最快的市場，預計複合年成長率將超過12%。這一快速擴張是由該地區特有的趨勢和動態所驅動的。

以下列出了神經調控設備市場的主要企業，它們總合佔最大的市場佔有率，並引領著行業趨勢：

  • Abbott Laboratories
  • Smith's Medical
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Boston Scientific Corp.
  • LivaNova PLC.
  • Medtronic
  • Nevro Corp.
  • Abbott
  • Stryker
  • Omron Corporation
  • Stimwave LLC
  • Koninklijke Philips NV
  • Kimberly Clark Corporation
  • EndoStim Inc.
  • Aleva neurotherapeutics SA
  • Cyberonics
  • DyAnsys, Inc.
  • NanoVibronix, Inc.
  • ElectroCore Inc.
  • 其他

神經調控設備市場的競爭格局高度集中，少數幾家大型企業，例如美敦力、雅培和波士頓科學，佔了市場主導地位。這些老牌企業憑藉著豐富的產品系列、強大的地域覆蓋以及在研發方面的大量投入，維持著主導。競爭的核心在於技術進步，特別是開發體積更小、更便於患者使用且電池續航力更長的植入式設備，以及整合能夠實現高階程式設計和資料管理的軟體平台。儘管市場高度集中於頂層企業，但也湧現出許多創新的小型公司和新興企業，尤其是在非侵入式領域。這些新參與企業透過專注於區隔應用和新技術，推動策略聯盟和併購，挑戰市場現狀。

  • 2025 年 6 月，Neuspera Medical 的整合薦骨神經調節 (iSNM) 系統獲得 FDA核准，用於治療急性尿失禁(UUI)，無需植入電池，從而為患者提供更舒適的體驗。
  • 2025 年 3 月，Neuronica 的下一代閉合迴路自適應 DBS 系統 AlphaDBS 獲得了 CE 認證。
  • 2025 年 2 月，美國FDA核准了美敦力公司的 BrainSense 自適應深部腦部刺激 (aDBS) 系統。

神經調控設備市場區隔

  • 神經調控設備市場趨勢（依設備分類）
  • 脊髓刺激設備
  • 深層腦部刺激器
  • 薦骨神經刺激器
  • 迷走神經刺激設備
  • 其他
  • 神經調控設備市場按應用領域分類的趨勢
  • 疼痛管理
  • 尿失禁和糞便失禁
  • 神經系統疾病
  • 呼吸系統疾病
  • 其他
  • 神經調控設備市場趨勢（按類型分類）
  • 侵入性
  • 非侵入性
  • 神經調控設備市場最終用戶趨勢
  • 醫院
  • 專科診所
  • 其他
  • 神經調控設備市場的區域趨勢
  • 北美神經調控設備市場
  • 美國神經調控設備市場
  • 加拿大神經調控設備市場
  • 墨西哥神經調控設備市場
  • 歐洲神經調控設備市場
  • 英國神經調控設備市場
  • 德國神經調控設備市場
  • 法國神經調控設備市場
  • 義大利神經調控設備市場
  • 西班牙神經調控設備市場
  • 其他歐洲神經調控設備市場
  • 亞太地區神經調控設備市場
  • 中國神經調控設備市場
  • 日本神經調控設備市場
  • 印度神經調控設備市場
  • 澳洲神經調控設備市場
  • 韓國神經調控設備市場
  • 亞太地區其他神經調控設備市場
  • 世界其他地區神經調控設備市場
  • 南美洲神經調控設備市場
  • 中東神經調控設備市場
  • 非洲神經調控設備市場

利用人工智慧進行影響分析

人工智慧驅動的創新正在深刻地改變神經調控設備市場，推動該領域從「一刀切」的靜態治療轉向高度個人化、動態和自適應的療法。人工智慧的一項關鍵影響是閉合迴路系統的發展。與提供固定刺激的傳統開迴路設備不同，人工智慧主導的設備能夠利用來自神經活動、患者報告症狀和生理指標的即時數據自動調整刺激參數。這不僅提高了治療效果，還最大限度地減少了副作用和臨床醫生手動重新編程的負擔。人工智慧演算法分析來自神經影像、患者病歷和裝置回饋的大量資料集，以預測治療反應、最佳化電極放置，並創建患者大腦的個人化「數位孿生」模型，用於治療方案模擬。這種向智慧、自主和響應式設備的轉變正在推動下一代神經調控技術的發展，有望為慢性疼痛、運動障礙和精神疾病帶來更有效、更精準、更以患者為中心的治療方案。

這主要是由於醫療技術供應鏈的全球化，即使是美國製造的設備也常常依賴大量進口零件。因此，關稅直接推高了製造成本，進而推高價格，並可能阻礙這些改變生命的技術的普及。這種情況也嚴重擾亂了供應鏈，迫使企業自行承擔或轉嫁成本，或透過供應商多元化或調整生產資源來徹底重組營運。雖然這可能為國內製造業帶來策略機遇，但也帶來了巨大的不確定性和複雜性，對大型成熟企業和小型創新新興企業都構成風險。最終，關稅成為阻礙醫療保健產業關鍵領域的一大阻力。

目錄

第1章 神經調控設備市場報告概述

  • 調查範圍
  • 市場區隔
  • 市場假設

2. 神經調控設備市場摘要整理

  • 市場概覽

第3章：神經調控設備市場關鍵因素分析

  • 市場促進因素
    • 慢性病和神經系統疾病盛行率不斷上升
    • 向微創手術過渡
    • 技術和創新方面的進步
    • 有利的監管和報銷環境
  • 市場阻礙與課題
    • 設備和手術高成本
    • 嚴格而複雜的法規結構
    • 手術相關的風險和併發症
    • 技術和可用性問題
  • 市場機遇
    • 「智慧」與非侵入式科技的興起

第4章 影響分析

  • 人工智慧驅動的創新和應用
  • 美國關稅的影響分析

第5章 監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章 神經調控設備市場－波特五力分析

第7章 神經調控設備市場評估

  • 依設備類型
    • 脊髓刺激設備
    • 深層腦部刺激器
    • 薦骨神經刺激器
    • 迷走神經刺激設備
    • 其他
  • 透過使用
    • 疼痛管理
    • 尿失禁和糞便失禁
    • 神經系統疾病
    • 呼吸系統疾病
  • 按類型
    • 侵入性
    • 非侵入性
  • 最終用戶
    • 醫院
    • 專科診所
  • 地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 其他地區

第8章 競爭情勢

第9章Start-Ups資金籌措與投資趨勢

10. 神經調控設備市場中的公司與產品概況

  • Abbott Laboratories
  • Smith's Medical
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Boston Scientific Corp.
  • LivaNova PLC.
  • Medtronic
  • Nevro Corp.
  • Abbott
  • Stryker
  • Omron Corporation
  • Stimwave LLC
  • Koninklijke Philips NV
  • Kimberly Clark Corporation
  • EndoStim Inc.
  • Aleva neurotherapeutics SA
  • Cyberonics
  • DyAnsys, Inc.
  • NanoVibronix, Inc.
  • ElectroCore Inc.

第11章：KOL視角

第12章計劃方法

第13章：關於 DelveInsight

第14章 免責聲明和聯絡我們

Product Code: DIMDCL0029

Neuromodulation Devices Market Summary

  • The global neuromodulation devices market is expected to increase from USD 7,862.04 million in 2024 to USD 16,111.10 million by 2032, reflecting strong and sustained growth.
  • The global neuromodulation devices market is growing at a CAGR of 9.44% during the forecast period from 2025 to 2032.
  • The market for neuromodulation devices is growing rapidly, fueled by the rising global prevalence of chronic diseases like pain, epilepsy, and depression. This growth is also driven by significant technological advancements that have made devices smaller, smarter, and more effective. Favorable regulatory policies and better reimbursement coverage are also making these treatments more accessible. Overall, the increasing demand for effective, long-term therapeutic options for neurological and chronic conditions is creating a strong and sustained market.
  • The leading companies operating in the neuromodulation devices market include Abbott Laboratories, Smith's Medical, B. Braun Melsungen AG, Baxter International Inc., Boston Scientific Corp., LivaNova PLC., Medtronic, Nevro Corp., Abbott, Stryker, Omron Corporation, Stimwave LLC, Koninklijke Philips NV, Kimberly Clark Corporation, EndoStim Inc., Aleva neurotherapeutics SA, Cyberonics, DyAnsys, Inc., NanoVibronix, Inc., ElectroCore Inc., and Others.
  • North America is expected to remain a dominant force in the neuromodulation devices market, driven by the high burden of chronic pain and neurological disorders, increasing awareness initiatives, supportive government programs, and continuous product innovations with frequent FDA approvals.
  • In the device type segment of the neuromodulation devices market, the spinal cord stimulators devices category is estimated to account for the largest market share in 2024.

Factors Contributing to the Growth of the Neuromodulation Devices Market

  • Rising Prevalence of Chronic and Neurological Disorders leading to a Surge in the Neuromodulation Devices Market: There is a growing global burden of conditions that neuromodulation devices are designed to treat. This includes the increasing incidence of chronic pain, epilepsy, Parkinson's disease, and treatment-resistant depression. As these conditions become more widespread, the demand for effective, long-term therapeutic solutions has surged.
  • Technological Advancements: continuous innovation is acting as a powerful catalyst for market expansion. Recent advances include the development of smaller, more powerful, and rechargeable devices, which reduce surgical burden and extend device lifespan, enhancing patient convenience. The emergence of "closed-loop" neuromodulation systems, such as adaptive deep brain stimulation, represents a paradigm shift by enabling real-time monitoring of neural activity and delivering stimulation only when required. This not only enhances therapeutic efficacy but also minimizes side effects and optimizes energy use. Moreover, the expanding application of neuromodulation in conditions beyond movement disorders, such as depression, chronic pain, epilepsy, and even sleep disorders, broadens the addressable market significantly. Collectively, the convergence of rising disease prevalence and rapid technological progress is reinforcing neuromodulation's role as a transformative solution in managing complex, long-term neurological and chronic conditions.

Shift Towards Minimally Invasive Procedures: Both patients and healthcare providers are increasingly favoring less invasive treatment options, a trend that strongly supports the adoption of neuromodulation devices. Implantable neuromodulation procedures are often regarded as a less invasive alternative to traditional surgeries for managing chronic pain, movement disorders, or urological conditions. Compared with open surgical interventions, they typically offer smaller incisions, shorter hospital stays, faster recovery times, and reduced postoperative complications, which translates into improved patient satisfaction and lower healthcare costs.

Beyond these procedural benefits, innovations such as percutaneous implantation techniques, miniaturized leads, and MRI-compatible devices have further reduced surgical risks while making these procedures more accessible to a broader patient population. Importantly, minimally invasive neuromodulation is also gaining traction in outpatient and ambulatory surgical settings, aligning with the healthcare industry's shift toward value-based care and cost efficiency. As reimbursement policies in many markets expand to include neuromodulation therapies, and as device manufacturers continue refining delivery methods, the less invasive nature of these interventions is expected to remain a major adoption driver across both developed and emerging healthcare systems.

Neuromodulation Devices Market Report Segmentation

This neuromodulation devices market report offers a comprehensive overview of the global neuromodulation devices market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by by Device Type (Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Vagus Nerve Stimulators, and Others), Application (Pain Management, Urinary & Faecal Incontinence, Neurological Disorders, Respiratory Disorders, and Others), Type (Invasive, Non-Invasive), End-Users (Hospitals, Specialty Clinics, and Others), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing neuromodulation devices market.

Neuromodulation devices are medical technologies that alter nerve activity by delivering a stimulus to specific areas of the nervous system. This stimulus can be electrical signals, magnetic fields, or chemical agents. The goal is to "modulate," or normalize, the function of nervous tissue that has been affected by disease or injury.

The market for neuromodulation devices is experiencing substantial growth, driven by a combination of factors. The rising global prevalence of chronic diseases such as chronic pain, neurological disorders like Parkinson's disease, epilepsy, and essential tremor, and mental health conditions like treatment-resistant depression is a primary driver. This increased disease burden has created a greater demand for effective, long-term therapeutic options. Furthermore, significant technological advancements have made these devices more effective and user-friendly. Innovations such as smaller, rechargeable implants, "closed-loop" systems that respond to neural activity in real time, and the development of non-invasive options like Transcranial Magnetic Stimulation (TMS) are expanding their adoption. Additionally, a more favorable regulatory environment and improved reimbursement policies are making these treatments more accessible to patients. This includes regulatory bodies approving a wider range of neurostimulators for new applications and insurers providing better coverage. Finally, the aging global population, which has a higher incidence of age-related neurological disorders and chronic pain, further contributes to the market's strong growth trajectory.

What are the latest Neuromodulation Devices Market Dynamics and Trends?

The growing market for neuromodulation devices is primarily driven by the escalating prevalence of various neurological conditions and the continuous introduction of innovative products by key industry players.

According to a major analysis from the Global Burden of Disease (GBD) Study 2021, published in The Lancet Neurology, neurological conditions collectively affected 3.4 billion people worldwide in 2021, representing 43% of the global population. This made them the leading cause of ill health and disability globally. The most prevalent of these conditions were tension-type headaches (affecting around 2 billion people) and migraines (affecting approximately 1.1 billion). Neuromodulation devices, such as those targeting the occipital nerves, are effective in managing chronic headaches and migraines by interrupting pain signals. Furthermore, the number of people with diabetic neuropathy has more than tripled since 1990, reaching 206 million in 2021, and neuromodulation devices are increasingly used to treat the nerve damage and associated pain.

The World Health Organization (WHO) reports that epilepsy affects around 50 million people globally. Neuromodulation devices like vagus nerve stimulators and responsive neurostimulators offer a critical treatment option, especially for patients with drug-resistant epilepsy, by reducing the frequency and severity of seizures.

The rise in cancer cases also contributes to the market. According to the latest GLOBOCAN 2022 estimates, there were about 20 million new cancer cases and 9.7 million deaths worldwide, with a 5-year prevalence of 53.5 million cases. The most common cancers were lung (2.48M cases), breast (2.30M), colorectal (1.93M), prostate (1.47M), and stomach (0.97M). Overall, 1 in 5 people will develop cancer during their lifetime, and 1 in 9 men and 1 in 12 women will die from it. While incidence is higher in high-income countries, mortality rates remain disproportionately high in low- and middle-income regions due to limited access to early detection and treatment. Looking ahead, global cancer cases are projected to rise to 35 million by 2050, a 77% increase from 2022. Many cancer patients experience neuropathic pain, which is often difficult to manage with conventional treatments. Advanced neuromodulation devices are being used to provide significant pain relief for these patients.

The continuous stream of new product introductions and regulatory approvals is a significant driver of the neuromodulation devices market. A notable example is the FDA approval in February 2025 of Medtronic's BrainSense Adaptive Deep Brain Stimulation (aDBS) system for Parkinson's disease, the first adaptive or "closed-loop" DBS technology to reach the market. Unlike conventional DBS systems that deliver fixed, continuous stimulation, the aDBS platform monitors patients' brain activity in real time, focusing on local field potentials (LFPs) and beta-band oscillations, which are biomarkers of Parkinson's motor symptoms. The system then dynamically adjusts stimulation parameters to align with the patient's neurological state across various conditions, such as medication cycles, rest, and physical activity. This capability not only enhances therapeutic precision but also reduces unnecessary stimulation, potentially improving outcomes while minimizing side effects like dyskinesia. Moreover, the addition of the BrainSense Electrode Identifier simplifies programming and enables clinicians to personalize therapy more efficiently, setting a new benchmark in the evolution of brain modulation technologies.

The neuromodulation devices market faces significant restraints and challenges despite its growth. A primary obstacle is the high cost of both the devices and the surgical procedures required for implantation, which limits accessibility, particularly in developing countries. This issue is compounded by a shortage of trained professionals, as the successful application of this therapy requires a specialized, multidisciplinary team, and the lack of such expertise can lead to suboptimal patient outcomes. Furthermore, the market is constrained by stringent regulatory frameworks; neuromodulation devices are classified as high-risk, leading to a long and complex approval process that can delay the commercialization of new innovations. Finally, patient and physician hesitation also serves as a barrier. Patients may be apprehensive about undergoing an invasive surgery, while some physicians may lack awareness or prefer traditional, more familiar treatment methods over neuromodulation.

Neuromodulation Devices Market Segment Analysis

Neuromodulation Devices Market by Device Type (Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Vagus Nerve Stimulators, and Others), Application (Pain Management, Urinary & Faecal Incontinence, Neurological Disorders, Respiratory Disorders, and Others), Type (Invasive, Non-Invasive), End-Users (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

By Device Type: Spinal Cord Stimulator Dominates the Market

The spinal cord stimulator category accounted for over 45% of the global neuromodulation devices market share in 2024, driven largely by mainstream adoption. According to the World Health Organization (2023), there were approximately 619 million cases of lower back pain (LBP), a figure expected to climb to 843 million by 2050. In parallel, the European Pain Federation (2023) reported that around 740 million people globally experience at least one episode of severe pain during their lifetime, with nearly 20% developing chronic pain lasting more than three months. This growing burden of chronic pain highlights the urgent need for effective and sustainable pain management solutions.

Spinal cord stimulators (SCS) have gained traction as they provide a minimally invasive, drug-free, and reversible therapy option. By delivering targeted electrical impulses to the spinal cord, these devices block pain signals before they reach the brain, significantly improving patient quality of life. The rising incidence of chronic pain disorders is, therefore, expected to be a major driver of SCS adoption worldwide.

Furthermore, findings published by the NIH (2023) revealed that Failed Back Surgery Syndrome (FBSS) affects 10-40% of patients following spinal surgeries. With the growing volume of spinal procedures for conditions such as herniated discs, spinal stenosis, and degenerative disc disease, the prevalence of FBSS continues to rise. Since repeated surgeries carry higher risks and often fail to deliver lasting pain relief, spinal cord stimulators are increasingly being recognized as an effective alternative. Their ability to reduce dependency on opioids, improve functional outcomes, and lower long-term healthcare costs makes them a preferred treatment choice, particularly for patients with FBSS and chronic neuropathic pain.

Emerging regulatory approvals are catalyzing market growth by enabling easier access to advanced SCS technologies:

In April 2024, Medtronic gained FDA approval for Inceptiv(TM), the first closed-loop SCS system to automatically adjust stimulation using real-time biological feedback (evoked compound action potentials, or ECAPs), maintaining optimal therapy even during daily movement. It is also the only FDA-approved closed-loop system offering full-body 3T MRI access with no restrictions, and is touted as the smallest and thinnest fully implantable SCS device.

In April 2023, Biotronik received FDA approval for its Prospera SCS System, featuring RESONANCE, the first multiphase stimulation paradigm, and Embrace One, a patient-centric care model offering automatic, objective, daily remote monitoring, ongoing management, and support. The system also includes HomeStream remote management, rechargeable implants, and full-body MRI compatibility

Each of these advancements highlights the trajectory of the SCS market, shifting from traditional, fixed-output devices requiring routine in-clinic adjustments, to intelligent, adaptive systems that emphasize remote care, personalization, and workflow efficiency.

By Application: Pain Management Categroy Dominate the Market

The pain management segment dominates the neuromodulation devices market, contributing nearly 58% of global revenue in 2024. This domicance is primarily due to the vast and growing population suffering from chronic pain, a condition that poses a significant global health and economic burden. The escalating opioid crisis has propelled a major shift in healthcare, favoring non-addictive, drug-free alternatives like neuromodulation. These devices are increasingly seen as a safe and effective long-term solution. This trend is further amplified by significant technological advancements, including the development of more sophisticated, user-friendly, and effective devices such as spinal cord stimulators. These innovations, coupled with favorable reimbursement policies and increasing awareness among both patients and healthcare providers, have solidified pain management's leading position in the market.

By Type: Invasive Categroy Dominate the Market

In 2024, the invasive neuromodulation devices category accounted for over 85% of the global market share due to their established clinical effectiveness, broad adoption, and strong support from regulatory approvals and reimbursement frameworks. Invasive devices such as spinal cord stimulators, deep brain stimulators, vagus nerve stimulators, and sacral nerve stimulators are widely used for chronic pain, Parkinson's disease, epilepsy, depression, and urinary incontinence, with proven outcomes that drive physician and patient confidence.

Recent technological advancements, including closed-loop stimulation, multiphase waveforms, miniaturized and MRI-compatible implants, and remote monitoring, have further enhanced their safety, efficacy, and usability. Chronic pain remains the largest driver, with spinal cord stimulators dominating given the rising prevalence of lower back pain and failed back surgery syndrome. Additionally, major players such as Medtronic, Abbott, Boston Scientific, Nevro, Biotronik, and Saluda continue to invest heavily in invasive solutions, unlike the fragmented non-invasive segment, which remains limited by narrower clinical validation and adoption. Together, these factors solidified the dominance of invasive neuromodulation devices in the global market in 2024.

By End-Users: Hospitals Dominate the Market

Hospitals dominated the global neuromodulation devices market in 2024, accounting for over 85% of the market share, and are expected to maintain leadership in terms of both revenue growth and CAGR during the forecast period. This dominance stems from the fact that hospitals serve as the primary centers for conducting complex surgical implantations of devices such as spinal cord stimulators, deep brain stimulators, and vagus nerve stimulators, which require advanced infrastructure, skilled neurosurgeons, and multidisciplinary care teams. Hospitals also provide comprehensive pre-operative evaluation, intraoperative monitoring, and post-operative rehabilitation, making them the preferred treatment setting for both patients and physicians. Furthermore, hospitals benefit from better reimbursement frameworks, enabling greater adoption of high-cost implantable neuromodulation devices. The rising burden of chronic pain, neurological disorders, and failed back surgery syndrome has increased hospital admissions and surgical volumes, further driving utilization. In addition, continuous technological upgrades, partnerships with MedTech companies, and participation in clinical trials strengthen hospitals' role as the central hubs for neuromodulation therapies. In contrast, outpatient centers and clinics, while growing, are largely limited to follow-up care or non-invasive neuromodulation, which contributes to their smaller market share. These factors collectively explain why hospitals remain the dominant end user in the neuromodulation devices market.

Neuromodulation Devices Market Regional Analysis

North America Neuromodulation Devices Market Trends

North America, led by the U.S., accounted for a dominant ~55% share of the global neuromodulation devices market in 2024, due to a combination of factors that create a highly favorable environment for the development, adoption, and commercialization of these technologies.

According to the CDC (2023), in 2021, 20.9% of U.S. adults (51.6M) reported chronic pain, with 6.9% (17.1M) experiencing high-impact chronic pain that limits daily activities. Additionally, around 2.9 million adults were living with active epilepsy (CDC, 2024), while the Alzheimer's Association (2024) reported 6.9 million Americans aged 65+ with Alzheimer's disease. Parkinson's disease prevalence is also rising, with nearly 90,000 new cases annually and over 1 million people affected, expected to reach 1.2 million by 2030 (Parkinson's Foundation, 2022).

Europe Neuromodulation Devices Market Trends

The neuromodulation devices market in Europe is dynamic and expanding, ranking second only to North America and accounting for approximately 21% of the global market share in 2024. This growth is driven by several key trends, including the rising prevalence of chronic conditions and an aging population, which together create a significant patient pool for conditions like Parkinson's disease, chronic pain, and epilepsy. Technological advancements are also a major catalyst, with the market seeing a rise in "smart," closed-loop systems, as well as smaller, rechargeable, and non-invasive devices that improve patient outcomes and comfort. Furthermore, while the regulatory and reimbursement landscape can be complex, many major European countries have established frameworks that support the adoption of these technologies. This growth is further propelled by the strong presence of global industry leaders, which drives continuous innovation and new product launches in the region.

Asia-Pacific Neuromodulation Devices Market Trends

The Asia-Pacific region is emerging as the fastest-growing market for neuromodulation devices globally, with a projected compound annual growth rate (CAGR) of over 12%. This rapid expansion is driven by a unique set of regional trends and dynamics.

Who are the major players in the Neuromodulation Devices Market?

The following are the leading companies in the Neuromodulation Devices market. These companies collectively hold the largest market share and dictate industry trends.

  • Abbott Laboratories
  • Smith's Medical
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Boston Scientific Corp.
  • LivaNova PLC.
  • Medtronic
  • Nevro Corp.
  • Abbott
  • Stryker
  • Omron Corporation
  • Stimwave LLC
  • Koninklijke Philips NV
  • Kimberly Clark Corporation
  • EndoStim Inc.
  • Aleva neurotherapeutics SA
  • Cyberonics
  • DyAnsys, Inc.
  • NanoVibronix, Inc.
  • ElectroCore Inc.
  • Others

How is the competitive landscape shaping the neuromodulation devices market?

The competitive landscape of the neuromodulation devices market is characterized by a high degree of concentration, with a few major players, namely Medtronic, Abbott Laboratories, and Boston Scientific, holding a dominant market share. These established companies maintain their lead through extensive product portfolios, strong geographical presence, and significant investments in research and development. The competition is shaping around technological advancements, particularly in developing smaller, more patient-friendly implantable devices with longer battery life, and integrating software platforms that allow for advanced programming and data management. While the market is highly concentrated at the top, it is also seeing an influx of innovative, smaller companies and startups, particularly in the non-invasive segment. These new entrants are focusing on niche applications and new technologies to challenge the status quo, driving strategic partnerships, mergers, and acquisitions as larger players seek to broaden their product offerings and stay ahead in this rapidly evolving field.

Recent Developmental Activities in the Neuromodulation Devices Market

  • In June 2025, Neuspera Medical's integrated sacral neuromodulation (iSNM) system received FDA approval to treat urinary urge incontinence (UUI) with no implantable battery, offering a more comfortable patient experience.
  • In March 2025, Newronika's AlphaDBS, a next-generation closed-loop adaptive DBS system, received CE Mark.
  • In February 2025, the U.S. FDA has approved Medtronic's BrainSense Adaptive Deep Brain Stimulation (aDBS) system, which is the first of its kind for treating Parkinson's disease.

Neuromodulation Devices Market Segmentation

  • Neuromodulation Devices Device Type Exposure
  • Spinal Cord Stimulators
  • Deep Brain Stimulators
  • Sacral Nerve Stimulators
  • Vagus Nerve Stimulators
  • Others
  • Neuromodulation Devices Application Exposure
  • Pain Management
  • Urinary & Faecal Incontinence
  • Neurological Disorders
  • Respiratory Disorders
  • Others
  • Neuromodulation Devices Type Exposure
  • Invasive
  • Non-Invasive
  • Neuromodulation Devices End-Users Exposure
  • Hospitals
  • Specialty Clinics
  • Others
  • Neuromodulation Devices Geography Exposure
  • North America Neuromodulation Devices Market
  • United States Neuromodulation Devices Market
  • Canada Neuromodulation Devices Market
  • Mexico Neuromodulation Devices Market
  • Europe Neuromodulation Devices Market
  • United Kingdom Neuromodulation Devices Market
  • Germany Neuromodulation Devices Market
  • France Neuromodulation Devices Market
  • Italy Neuromodulation Devices Market
  • Spain Neuromodulation Devices Market
  • Rest of Europe Neuromodulation Devices Market
  • Asia-Pacific Neuromodulation Devices Market
  • China Neuromodulation Devices Market
  • Japan Neuromodulation Devices Market
  • India Neuromodulation Devices Market
  • Australia Neuromodulation Devices Market
  • South Korea Neuromodulation Devices Market
  • Rest of Asia-Pacific Neuromodulation Devices Market
  • Rest of the World Neuromodulation Devices Market
  • South America Neuromodulation Devices Market
  • Middle East Neuromodulation Devices Market
  • Africa Neuromodulation Devices Market

Impact Analysis

AI-Powered Innovations and Applications:

AI-powered innovations are profoundly transforming the neuromodulation devices market, moving the field from "one-size-fits-most" static therapies to highly personalized, dynamic, and adaptive treatments. The primary impact of AI is the development of closed-loop systems. Unlike traditional open-loop devices that deliver a fixed stimulus, AI-driven devices use real-time data from neural activity, patient-reported symptoms, and physiological markers to automatically adjust stimulation parameters. This not only enhances therapeutic efficacy but also minimizes side effects and the burden on clinicians for manual reprogramming. AI algorithms analyze vast datasets from neuroimaging, patient history, and device feedback to predict treatment responses, optimize electrode placement, and create personalized "digital twins" of a patient's brain for simulated therapy planning. This shift towards intelligent, autonomous, and responsive devices is driving the next generation of neuromodulation, promising a future of more effective, precise, and patient-centric therapies for chronic pain, movement disorders, and psychiatric conditions.

U.S. Tariff Impact Analysis on the Neuromodulation Devices Market:

The implementation of U.S. tariffs on medical device components is creating significant challenges for the neuromodulation devices market. This is mainly due to the globalized supply chains of medical technology, where even devices manufactured in the U.S. often rely on a substantial number of imported parts. As a result, the tariffs are directly increasing manufacturing costs, which in turn puts pressure on pricing and could potentially hinder the adoption of these life-changing technologies. This situation is also causing major supply chain disruptions, forcing companies to either absorb the costs, pass them on, or completely restructure their operations by diversifying suppliers or even reshoring production. While this may offer a strategic opportunity for domestic manufacturing, it simultaneously introduces significant uncertainty and complexity, posing a risk to both large, established companies and smaller, innovative startups. Ultimately, the tariffs are a major headwind that threatens to slow down a crucial sector of the healthcare industry.

How This Analysis Helps Clients

  • Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
  • Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
  • Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
  • Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the neuromodulation devices market report study

  • Market size analysis for the current neuromodulation devices market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the neuromodulation devices market.
  • Various opportunities available for the other competitors in the neuromodulation devices market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current neuromodulation devices market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for the neuromodulation devices market growth in the future?

Frequently Asked Questions for the Neuromodulation Devices Market

1. What is the growth rate of the neuromodulation devices market?

  • The neuromodulation devices market is estimated to grow at a CAGR of 9.44% during the forecast period from 2025 to 2032.

2. What is the market for neuromodulation devices?

  • The neuromodulation devices market was valued at USD 7,862.04 million in 2024, and is expected to reach USD 16,111.10 million by 2032.

3. Which region has the highest share in the neuromodulation devices market?

  • North America is expected to remain a dominant force in the neuromodulation devices market, driven by the high burden of chronic pain and neurological disorders, increasing awareness initiatives, supportive government programs, and continuous product innovations with frequent FDA approvals.

4. What are the drivers for the neuromodulation devices market?

  • The market for neuromodulation devices is growing rapidly, fueled by the rising global prevalence of chronic diseases like pain, epilepsy, and depression. This growth is also driven by significant technological advancements that have made devices smaller, smarter, and more effective. Favorable regulatory policies and better reimbursement coverage are also making these treatments more accessible. Overall, the increasing demand for effective, long-term therapeutic options for neurological and chronic conditions is creating a strong and sustained market.

5. Who are the key players operating in the neuromodulation devices market?

  • Some of the key market players operating in the neuromodulation devices market include Abbott Laboratories, Smith's Medical, B. Braun Melsungen AG, Baxter International Inc., Boston Scientific Corp., LivaNova PLC., Medtronic, Nevro Corp., Abbott, Stryker, Omron Corporation, Stimwave LLC, Koninklijke Philips NV, Kimberly Clark Corporation, EndoStim Inc., Aleva neurotherapeutics SA, Cyberonics, DyAnsys, Inc., NanoVibronix, Inc., ElectroCore Inc., and Others.

Table of Contents

1. Neuromodulation Devices Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumption

2. Neuromodulation Devices Market Executive Summary

  • 2.1 Market at Glance

3. Neuromodulation Devices Market Key Factors Analysis

  • 3.1 Neuromodulation Devices Market Drivers
    • 3.1.1 Rising Prevalence of Chronic and Neurological Disorders
    • 3.1.2 Shift Towards Minimally invasive Procedures
    • 3.1.3 Advancements in Technology and Innovation
    • 3.1.4 Favorable Regulatory and Reimbursement Landscape
  • 3.2 Neuromodulation Devices Market Restraints and Challenges
    • 3.2.1 High Cost of Devices and Procedures
    • 3.2.2 Stringent and Complex Regulatory Frameworks
    • 3.2.3 Risks and Complications Associated with Surgery
    • 3.2.4 Technical and Usability Issues
  • 3.3 Neuromodulation Devices Market Opportunity
    • 3.3.1 Rise of "Smart" and Non-Invasive Technologies

4. Impact Analysis

  • 4.1 AI-Powered Innovations and Applications
  • 4.2 U.S. Tariff Impact Analysis

5. Regulatory Analysis

  • 5.1 The United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Neuromodulation Devices Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Consumers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Neuromodulation Devices Market Assessment

  • 7.1 By Device Type
    • 7.1.1 Spinal Cord Stimulators
    • 7.1.2 Deep Brain Stimulators
    • 7.1.3 Sacral Nerve Stimulators
    • 7.1.4 Vagus Nerve Stimulators
    • 7.1.5 Others
  • 7.2 By Application
    • 7.2.1 Pain Management
    • 7.2.2 Urinary & Faecal Incontinence
    • 7.2.3 Neurological Disorders
    • 7.2.4 Respiratory Disorders
    • 7.2.5 Others
  • 7.3 By Type
    • 7.3.1 Invasive
    • 7.3.2 Non-Invasive
  • 7.4 By End-Users
    • 7.4.1 Hospitals
    • 7.4.2 Specialty Clinics
    • 7.4.3 Others
  • 7.5 By Geography
    • 7.5.1 North America
      • 7.5.1.1 United States Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.1.2 Canada Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.1.3 Mexico Neuromodulation Devices Market Size in USD million (2022-2032)
    • 7.5.2 Europe
      • 7.5.2.1 France Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.2.2 Germany Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.2.3 United Kingdom Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.2.4 Italy Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.2.5 Spain Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.2.6 Rest of Europe Neuromodulation Devices Market Size in USD million (2022-2032)
    • 7.5.3 Asia-Pacific
      • 7.5.3.1 China Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.3.2 Japan Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.3.3 India Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.3.4 Australia Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.3.5 South Korea Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.3.6 Rest of Asia-Pacific Neuromodulation Devices Market Size in USD million (2022-2032)
    • 7.5.4 Rest of the World (RoW)
      • 7.5.4.1 Middle East Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.4.2 Africa Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.4.3 South America Neuromodulation Devices Market Size In USD Million (2022-2032)

8. Competitive Landscape

9. Startup Funding & Investment Trends

10. Neuromodulation Devices Market Company and Product Profiles

  • 10.1 Abbott Laboratories
    • 10.1.1 Company Overview
    • 10.1.2 Company Snapshot
    • 10.1.3 Financial Overview
    • 10.1.4 Product Listing
    • 10.1.5 Entropy
  • 10.2 Smith's Medical
    • 10.2.1 Company Overview
    • 10.2.2 Company Snapshot
    • 10.2.3 Financial Overview
    • 10.2.4 Product Listing
    • 10.2.5 Entropy
  • 10.3 B. Braun Melsungen AG
    • 10.3.1 Company Overview
    • 10.3.2 Company Snapshot
    • 10.3.3 Financial Overview
    • 10.3.4 Product Listing
    • 10.3.5 Entropy
  • 10.4 Baxter International Inc.
    • 10.4.1 Company Overview
    • 10.4.2 Company Snapshot
    • 10.4.3 Financial Overview
    • 10.4.4 Product Listing
    • 10.4.5 Entropy
  • 10.5 Boston Scientific Corp.
    • 10.5.1 Company Overview
    • 10.5.2 Company Snapshot
    • 10.5.3 Financial Overview
    • 10.5.4 Product Listing
    • 10.5.5 Entropy
  • 10.6 LivaNova PLC.
    • 10.6.1 Company Overview
    • 10.6.2 Company Snapshot
    • 10.6.3 Financial Overview
    • 10.6.4 Product Listing
    • 10.6.5 Entropy
  • 10.7 Medtronic
    • 10.7.1 Company Overview
    • 10.7.2 Company Snapshot
    • 10.7.3 Financial Overview
    • 10.7.4 Product Listing
    • 10.7.5 Entropy
  • 10.8 Nevro Corp.
    • 10.8.1 Company Overview
    • 10.8.2 Company Snapshot
    • 10.8.3 Financial Overview
    • 10.8.4 Product Listing
    • 10.8.5 Entropy
  • 10.9 Abbott
    • 10.9.1 Company Overview
    • 10.9.2 Company Snapshot
    • 10.9.3 Financial Overview
    • 10.9.4 Product Listing
    • 10.9.5 Entropy
  • 10.10 Stryker
    • 10.10.1 Company Overview
    • 10.10.2 Company Snapshot
    • 10.10.3 Financial Overview
    • 10.10.4 Product Listing
    • 10.10.5 Entropy
  • 10.11 Omron Corporation
    • 10.11.1 Company Overview
    • 10.11.2 Company Snapshot
    • 10.11.3 Financial Overview
    • 10.11.4 Product Listing
    • 10.11.5 Entropy
  • 10.12 Stimwave LLC
    • 10.12.1 Company Overview
    • 10.12.2 Company Snapshot
    • 10.12.3 Financial Overview
    • 10.12.4 Product Listing
    • 10.12.5 Entropy
  • 10.13 Koninklijke Philips NV
    • 10.13.1 Company Overview
    • 10.13.2 Company Snapshot
    • 10.13.3 Financial Overview
    • 10.13.4 Product Listing
    • 10.13.5 Entropy
  • 10.14 Kimberly Clark Corporation
    • 10.14.1 Company Overview
    • 10.14.2 Company Snapshot
    • 10.14.3 Financial Overview
    • 10.14.4 Product Listing
    • 10.14.5 Entropy
  • 10.15 EndoStim Inc.
    • 10.15.1 Company Overview
    • 10.15.2 Company Snapshot
    • 10.15.3 Financial Overview
    • 10.15.4 Product Listing
    • 10.15.5 Entropy
  • 10.16 Aleva neurotherapeutics SA
    • 10.16.1 Company Overview
    • 10.16.2 Company Snapshot
    • 10.16.3 Financial Overview
    • 10.16.4 Product Listing
    • 10.16.5 Entropy
  • 10.17 Cyberonics
    • 10.17.1 Company Overview
    • 10.17.2 Company Snapshot
    • 10.17.3 Financial Overview
    • 10.17.4 Product Listing
    • 10.17.5 Entropy
  • 10.18 DyAnsys, Inc.
    • 10.18.1 Company Overview
    • 10.18.2 Company Snapshot
    • 10.18.3 Financial Overview
    • 10.18.4 Product Listing
    • 10.18.5 Entropy
  • 10.19 NanoVibronix, Inc.
    • 10.19.1 Company Overview
    • 10.19.2 Company Snapshot
    • 10.19.3 Financial Overview
    • 10.19.4 Product Listing
    • 10.19.5 Entropy
  • 10.20 ElectroCore Inc.
    • 10.20.1 Company Overview
    • 10.20.2 Company Snapshot
    • 10.20.3 Financial Overview
    • 10.20.4 Product Listing
    • 10.20.5 Entropy

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer & Contact Us

List of Tables

  • Table 1: Neuromodulation Devices Market in Global (2022-2032)
  • Table 2: Neuromodulation Devices Market in Global by Device Type (2022-2032)
  • Table 3: Neuromodulation Devices Market in Global by Application (2022-2032)
  • Table 4: Neuromodulation Devices Market in Global by Type (2022-2032)
  • Table 5: Neuromodulation Devices Market in Global by End-Users (2022-2032)
  • Table 6: Neuromodulation Devices Market in Global by Geography (2022-2032)
  • Table 7: Neuromodulation Devices Market in North America (2022-2032)
  • Table 8: Neuromodulation Devices Market in the United States (2022-2032)
  • Table 9: Neuromodulation Devices Market in Canada (2022-2032)
  • Table 10: Neuromodulation Devices Market in Mexico (2022-2032)
  • Table 11: Neuromodulation Devices Market in Europe (2022-2032)
  • Table 12: Neuromodulation Devices Market in France (2022-2032)
  • Table 13: Neuromodulation Devices Market in Germany (2022-2032)
  • Table 14: Neuromodulation Devices Market in United Kingdom (2022-2032)
  • Table 15: Neuromodulation Devices Market in Italy (2022-2032)
  • Table 16: Neuromodulation Devices Market in Spain (2022-2032)
  • Table 17: Neuromodulation Devices Market in the Rest of Europe (2022-2032)
  • Table 18: Neuromodulation Devices Market in Asia-Pacific (2022-2032)
  • Table 19: Neuromodulation Devices Market in China (2022-2032)
  • Table 20: Neuromodulation Devices Market in Japan (2022-2032)
  • Table 21: Neuromodulation Devices Market in India (2022-2032)
  • Table 22: Neuromodulation Devices Market in Australia (2022-2032)
  • Table 23: Neuromodulation Devices Market in South Korea (2022-2032)
  • Table 24: Neuromodulation Devices Market in Rest of Asia-Pacific (2022-2032)
  • Table 25: Neuromodulation Devices Market in the Rest of the World (2022-2032)
  • Table 26: Neuromodulation Devices Market in the Middle East (2022-2032)
  • Table 27: Neuromodulation Devices Market in Africa (2022-2032)
  • Table 28: Neuromodulation Devices Market in South America (2022-2032)
  • Table 29: Competitive Landscape
  • Table 30: Startup Funding & Investment Trends

List of Figures

  • Table 1: Neuromodulation Devices Market Drivers
  • Table 2: Neuromodulation Devices Market Restraints
  • Table 3: Neuromodulation Devices Market Opportunities
  • Table 4: AI-Powered Innovations in Neuromodulation Devices Market
  • Table 5: US Tariff Impact on Neuromodulation Devices Market
  • Table 6: Regulatory Analysis (US, EU, Japan, China)
  • Table 7: Porter's Five Forces Analysis
  • Table 8: Competitive Analysis
  • Table 9: Neuromodulation Devices Market in Global (2022-2032)
  • Table 10: Neuromodulation Devices Market in Global by Device Type (2022-2032)
  • Table 11: Neuromodulation Devices Market in Global by Application (2022-2032)
  • Table 12: Neuromodulation Devices Market in Global by Type (2022-2032)
  • Table 13: Neuromodulation Devices Market in Global by End-Users (2022-2032)
  • Table 14: Neuromodulation Devices Market in Global by Geography (2022-2032)
  • Table 15: Neuromodulation Devices Market in North America (2022-2032)
  • Table 16: Neuromodulation Devices Market in the United States (2022-2032)
  • Table 17: Neuromodulation Devices Market in Canada (2022-2032)
  • Table 18: Neuromodulation Devices Market in Mexico (2022-2032)
  • Table 19: Neuromodulation Devices Market in Europe (2022-2032)
  • Table 20: Neuromodulation Devices Market in France (2022-2032)
  • Table 21: Neuromodulation Devices Market in Germany (2022-2032)
  • Table 22: Neuromodulation Devices Market in United Kingdom (2022-2032)
  • Table 23: Neuromodulation Devices Market in Italy (2022-2032)
  • Table 24: Neuromodulation Devices Market in Spain (2022-2032)
  • Table 25: Neuromodulation Devices Market in the Rest of Europe (2022-2032)
  • Table 26: Neuromodulation Devices Market in Asia-Pacific (2022-2032)
  • Table 27: Neuromodulation Devices Market in China (2022-2032)
  • Table 28: Neuromodulation Devices Market in Japan (2022-2032)
  • Table 29: Neuromodulation Devices Market in India (2022-2032)
  • Table 30: Neuromodulation Devices Market in Australia (2022-2032)
  • Table 31: Neuromodulation Devices Market in South Korea (2022-2032)
  • Table 32: Neuromodulation Devices Market in Rest of Asia-Pacific (2022-2032)
  • Table 33: Neuromodulation Devices Market in the Rest of the World (2022-2032)
  • Table 34: Neuromodulation Devices Market in the Middle East (2022-2032)
  • Table 35: Neuromodulation Devices Market in Africa (2022-2032)
  • Table 36: Neuromodulation Devices Market in South America (2022-2032)
  • Table 37: Competitive Landscape
  • Table 38: Startup Funding & Investment Trends